首页> 外文期刊>Retina >Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat.
【24h】

Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat.

机译:乳酸角鲨胺可降低大鼠激光损伤模型中的脉络膜新生血管。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: To determine if systemically administered squalamine lactate, a novel aminosterol with antineoplastic and antiangiogenic activity, inhibits the development of experimental choroidal neovascularization membranes (CNVMs) induced by laser trauma in a rat model. METHODS: Twenty anesthetized male Brown-Norway rats received a series of 8 krypton red laser lesions per eye (647 nm, 0.05 second, 50 microm, 150 mW). One half the animals received an intraperitoneal injection of squalamine and the other one half received an injection of 5% dextrose in water, all performed in a masked fashion. Fundus photography and fluorescein angiography were performed at postlaser treatment days 14 and 28, and ocular tissues were processed for light microscopic examination following euthanasia of the rats on postlaser treatment day 28. RESULTS: Although fundus photography and fluorescein angiography yielded no statistically significant quantitative differences between the two groups, histologic analysis of the lesion sites revealed a partial but statistically significant reduction of experimental CNVM development in the squalamine-treated population. In particular, the squalamine-treated eyes (n = 20) demonstrated lesions (n = 149) with a mean CNVM thickness +/- SD of 47 +/- 11 microm, as compared with the control eyes (n = 20) that had lesions (n = 142) with a mean CNVM thickness +/- SD of 63 +/- 14 microm (P < 0.001). CONCLUSION: Systemically administered squalamine lactate partially reduced choroidal neovascular membrane development induced by laser trauma in this animal model. In conjunction with other existing and developing therapies, this agent may have a potential role in the treatment of human CNVM formation. Further study of squalamine lactate for treatment of neovascular eye disease is warranted.
机译:用途:为了确定是否全身给药乳酸角鲨胺,一种具有抗肿瘤和抗血管生成活性的新型氨基甾醇,可抑制大鼠模型中由激光创伤诱导的实验性脉络膜新血管形成膜(CNVM)的发展。方法:20只麻醉的雄性Brown-Norway大鼠每只眼受到一系列8个k红色激光损伤(647 nm,0.05秒,50 microm,150 mW)。一半的动物腹膜内注射角鲨胺,另一半的动物水中注射5%葡萄糖,所有这些都是以掩盖方式进行的。在激光治疗后第14天和第28天进行眼底照相和荧光素血管造影,在激光治疗后第28天对大鼠进行安乐死后,对眼组织进行光镜检查。两组,病变部位的组织学分析显示,在角鲨胺治疗的人群中,实验性CNVM发育部分但统计学上显着降低。特别是,经角鲨胺治疗的眼睛(n = 20)显示出病变(n = 149),而对照组的眼睛(n = 20)的平均CNVM厚度+/- SD为47 +/- 11微米。病变(n = 142),CNVM平均厚度+/- SD为63 +/- 14微米(P <0.001)。结论:在该动物模型中,全身给予乳酸角鲨胺乳酸盐可部分减少激光损伤引起的脉络膜新生血管膜的发育。结合其他现有和正在开发的疗法,该药物可能在治疗人类CNVM形成中具有潜在作用。有必要对乳酸角鲨胺的进一步治疗进行研究,以治疗新生血管性眼病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号